Proliferating Oligodendrocytes Are Present In Both Active And Chronic Inactive Multiple Sclerosis Plaques
Solanky M, Maeda Y, Ming X, Husar W, Li W, Cook S, Dowling P
J NeuroSci Res 2001 Aug 15;65(4):308-17
New Jersey Health Care System, Dept of Veterans Affairs, Neurology Service, East Orange, New Jersey
PMID# 11494366; UI# 21385484
The proliferation marker Ki-67 labels cell nuclei in the G(1), S, M, and G(2) phases of the cell cycle.
We used Ki-67 ImmunoHistoChemistry to quantify proliferating Glial Cells in Brain tissue sections from twenty-four patients, comprised of Multiple Sclerosis, normal Brains, and Other Neurological Disease controls.
Glial proliferation was greatly increased in MS Lesions when compared with control Brain White Matter.
Both actively DeMyelinating/early ReMyelinating plaques and chronic inactive plaques of long standing often displayed large numbers of Glial Cells in the proliferative cycle.
The bulk of these proliferating cells were of Oligodendroglial lineage in the MS plaques. Ki-67 positive Macrophage/Microglial lineage cells were largely restricted to acute lesions.
The finding of increased numbers of proliferating Oligodendroglia in most MS plaques, regardless of disease duration or activity state, indicates that the MS Brain is capable of recruiting unexpectedly large numbers of new Oligodendrocytes over long periods of time.
The factors within the MS plaque MicroEnvironment that provoke new Oligodendrocyte generation and their subsequent loss still need to be identified.
Copyright 2001 Wiley-Liss, Inc.
Contractile Speed And Fatigue Of Adductor Pollicis Muscle In Multiple Sclerosis
de Ruiter CJ, Jongen PJ, van Der Woude LH, de Haan A
Muscle Nerve 2001 Sep;24(9):1173-80
Vrije Univ, Institute for Fundamental and Clinical Human Movement Sciences, Faculty of Human Movement Sciences, van der Boechorststraat 9, 1081 BT Amsterdam, The Netherlands
PMID# 11494270; UI# 21385591
The purpose of the study was to investigate differences in contractile speed, force, and Fatigability of the Adductor Pollicis Muscle between 12 patients with Multiple Sclerosis (MS) and 8 sedentary control subjects matched for age and gender.
There were no differences between the patients with MS and control subjects with respect to the percentage of maximal muscle force that could be recruited during voluntary effort (95.5 +/- 3.9% and 98.2 +/- 2.0%, respectively, P = 0.10).
The stimulation frequency/force and force/velocity relationships, the rates of force development and relaxation, fatigue resistance, and the recovery rate of Adductor Pollicis Muscle.
However, previous results from the same group of MS patients showed that Quadriceps Femoris Muscle force and resistance to fatigue were reduced.
Therefore, our data support the clinical experience that, in patients with MS, lower limb muscle function is more or earlier affected than upper limb muscle function.
Copyright 2001 John Wiley & Sons, Inc.
Differential Release Of ß-Chemokines In Serum And CSF In Relapsing/Remitting Multiple Sclerosis
Sindern E, Niederkinkhaus Y, Henschel M, Ossege LM, Patzold T, Malin JP
Acta Neurol Scand 2001 Aug;104(2):88-91
BG-Kliniken Bergmannsheil, Depts of Neurology, Radiology, Ruhr-UnivBochum, FRG
PMID# 11493224; UI# 21384453
ß-Chemokines were recently demonstrated in active MS-lesions.
We tested whether MCP-1 and RANTES can also be detected in CSF and Serum of patients with MS and whether release is associated with Inflammatory Disease activity.
Materials And Methods
CSF and Serum from 34 patients with newly diagnosed Relapsing/Remitting MS (RR-MS), 17 patients with Viral Meningitis (VM) and 19 patients with Non-Inflammatory Neurological Diseases (NIND) were investigated by ELISA.
RR-MS patients underwent Lumbar Puncture and Gd-enhanced MRI examinations within 2 days.
MCP-1 was strong Intrathecally released in all patients.
Compared to NIND CSF-levels were increased in VM (P<0.001) and were decreased in RR-MS (P<0.05). RANTES was only detected in Serum in all patients.
Levels were higher in VM and RR-MS compared to NIND (P<0.05). A total of 14/34 RR-MS patients exhibited active Gd-enhancing Lesions on MRI.
They had lower MCP-1 levels in CSF (P<0.001) and Serum (P<0.05) and higher Serum levels of RANTES (P<0.05) as compared to patients without active lesions.
MCP-1 and RANTES are differentially released during acute attacks of RR-MS, which might reflect different ImmunRegulatory roles of these ß-Chemokines in RR-MS.
Frequency And Significance Of Anti-Ro (SS-A) AntiBodies In Multiple Sclerosis
de Andres C, Guillem A, Rodriguez-Mahou M, Lopez Longo FJ
Acta Neurol Scand 2001 Aug;104(2):83-7
Hospital general Universitario Gregorio Maranon, Depts of Neurology, Immunology and Rheumatology, Madrid, Spain
PMID# 11493223; UI# 21384452
To determine the frequency and significance of AntiNuclear (ANA), AntiCardiolipin (ACA) and Anti-Ro (SS-A) AntiBodies in Multiple Sclerosis (MS) patients.
ANA (indirect ImmunoFluorescence), ACA and anti-Ro (SS-A) AntiBodies (ELISA) were tested in Sera of 42 patients with Poser defined MS and 50 healthy individuals.
High levels of anti-Ro (SS-A) AntiBodies were found in 3 patients (7%) (vs 0 in the control group).
Two of them had normal salivary gland biopsy. Clinical MS form was Chronic/Progressive in 2 cases and Relapsing/Remitting in the third one.
Ten patients (23%) had low levels of ANA (vs 4%), none of them positive for Anti-Ro (SS-A) AntiBodies.
Only 1 patient (2%) with RR clinical form had ACA (vs 0). No clinical or NeuroRadiological differences with conventional MS patients were observed.
ANA, ACA and Anti-Ro (SS-A) AntiBodies in MS patients indicate an underlying AutoImmune Disease but our series suggests that they are an Epiphenomenon of a more diffuse Immunological dysfunction.